Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

Last week, US pharma giant Pfizer chairman and chief executive Albert Bourla presented at the JP Morgan Healthcare Conference ...

Pfizer has spent billions of dollars on acquisitions in the past few decades. Its biggest deals include Warner-Lambert, ...

The MarketWatch News Department was not involved in the creation of this content. SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, ...

With COVID sales falling and patent protections expiring, Pfizer is forecasting its 2026 revenue to be in the range of $59.5 billion to $62.5 billion. The midpoint of the projection ($61 billion) ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about a year. This time, the drug that delivered the positive readout is Tukysa, ...

Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today, the UK health technology assessor, National Institute ...

Pfizer PFE and AbbVie ABBV are both U.S. pharmaceutical giants with a strong leadership position in various therapeutic areas. For Pfizer, oncology sales comprise around 28% of its total revenues.

Texas Attorney General Ken Paxton has secured a $41.5M settlement with Pfizer (PFE) and Tris Pharma for allegedly providing adulterated pharmaceutical drugs to Texas children in violation of the Texas ...

Texas's top prosecutor on Wednesday announced the state had reached a $41.5 million settlement with US drugmakers Pfizer and Tris Pharma, over allegations of drug adulteration and defrauding the state ...